A randomized clinical trial investigating the relationship between aprotinin and hypercoagulabilityin off-pump coronary surgery

Anesthesia and Analgesia

Volumn 109, Issue 5, 2009, Pages 1387-1394

  Desai, Pranjal H ^a   Kurian, Dinesh ^a   Thirumavalavan, Nannan ^a   Desai, Sneha P ^a   Ziu, Pluen ^a   Grant, Michael ^b   White, Charles ^b   Landis, R Clive ^c   Poston, Robert S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; APROTININ; SODIUM CHLORIDE; THROMBIN; TROPONIN I; FIBRINOLYTIC AGENT; PEPTIDE FRAGMENT; PROTEINASE ACTIVATED RECEPTOR 1; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2;

ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY SINUS; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKOCYTE; MAJOR CLINICAL STUDY; OFF PUMP CORONARY SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INJURY; STROKE; SYSTEMIC CIRCULATION; THROMBOCYTE FUNCTION; THROMBOSIS; VEIN GRAFT DISEASE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; GRAFT OCCLUSION; METABOLISM; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE ADHESIVENESS; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; WOUND HEALING;

APROTININ; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CORONARY ARTERY BYPASS, OFF-PUMP; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; PEPTIDE FRAGMENTS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; PROTHROMBIN; RECEPTOR, PAR-1; THROMBIN; THROMBOSIS; TREATMENT OUTCOME; WOUND HEALING;

EID: 70350719521     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181b81068     Document Type: Article

References (28)

1. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389
2. Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969;34:204-215
3. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of lowdose aspirin. Blood 2001;98:2423-2431
4. Manchio JV, Gu J, Romar L, Brown J, Gammie J, Pierson RN III, Griffith B, Poston RS. Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. Ann Thorac Surg 2005;79:1991-1998 (Pubitemid 40804176)
5. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, Pierson RN III, Griffith BP. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122-130
6. Kon ZN, Kwon MH, Kallam S, Sangrampurkar R, Ozeki T, Brown EN, Romar LG, Pierson RN, Gammie JS, Brown JM, Griffith BP, Poston RS. Off-pump coronary artery bypass leads to a regional hypercoagulable state not detectable using systemic markers. Innovations Phila Pa 2006;1:232-238
7. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T. Offpump coronary artery bypass sacrifices graft patency: metaanalysis of randomized trials. J Thorac Cardiovasc Surg 2007; 133:e2-e3
8. Lim E, Drain A, Davies W, Edmonds L, Rosengard BR. A systematic review of randomized trials comparing revascularization rate and graft patency of off-pump and conventional coronary surgery. J Thorac Cardiovasc Surg 2006;132:1409-1413
9. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003;304:855-861
10. Day JRS, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004;110:2597-2600
11. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 2005;79:1545-1550
12. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007;21:103-113
13. Westaby S. Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 2008;135:487-491
14. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, Lee A, Connerney I, Avari T, Christenson R, Tandry U, Griffith BP. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104 -10; discussion 110-111
15. Burris N, Schwartz K, Tang CM, Jafri MS, Schmitt J, Kwon MH, Toshinaga O, Gu J, Brown J, Brown E, Pierson R III, Poston R. Catheter-based infrared light scanner as a tool to assess conduit quality in coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;133:419-427
16. Muluk SC, Vorp DA, Severyn DA, Gleixner S, Johnson PC, Webster MW. Enhancement of tissue factor expression by vein segments exposed to coronary arterial hemodynamics. J Vasc Surg 1998;27:521-527
17. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Hemost 2005;94:488-492
18. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH Jr. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106: 1-9; discussion 9-10
19. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1. J Thorac Cardiovasc Surg 2000;120:370-378
20. Maquelin KN, Nieuwland R, Lentjes EG, Boing AN, Mochtar B, Eijsman L, Sturk A. Aprotinin administration in the pericardial cavity does not prevent platelet activation. J Thorac Cardiovasc Surg 2000;120:552-557
21. Becker RC, Spencer FA, Li Y, Ball SP, Ma Y, Hurley T, Hebert J. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J Am Coll Cardiol 1999;34:1020-1027
22. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935
23. Moliterno DJ, Becker RC, Jennings LK, Berman G, Yang B, Strony J, Vettri E, Harrington RA. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. American College of Cardiology Meeting, New Orleans, March 24, 2007
24. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-2331
25. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-783
26. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-479
27. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008;48(1 suppl):2S-30S
28. Grant MC, Kon Z, Joshi A, Christenson E, Kallam S, Burris N, Gu J, Poston RS. Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass. Ann Thorac Surg 2008;86:815-822